APA (7th ed.) Citation

Fautrel, B., Bouhnik, Y., Salliot, C., Carbonnel, F., Fumery, M., Bernardeau, C., . . . investigators, t. P. Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study. Adis, Springer Healthcare.

Chicago Style (17th ed.) Citation

Fautrel, Bruno, et al. Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study. Adis, Springer Healthcare.

MLA (9th ed.) Citation

Fautrel, Bruno, et al. Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study. Adis, Springer Healthcare.